I find this intriguing:
"It also recorded a $481 million charge due to a review of its research and development work that reduced the estimated value of products in its drug development pipeline. "
I have to be honest, I have no idea what that means or the financial stuff behind it (how did that process cost money? What did they pay for? What value were they counting before that they are not now?) In truth I don't even know what question to ask to understand that above quote. That being said, it is clear that Dr. Levin has been busy.
loss for quarter not dilluted (as nine month figure is) for options etc, some new but trivial invstigation filing and goes uo 2% ?? i'm all positive about medium and long term, very positive, but what explains the 2% daily???
the market seems to like SOMETHING. Of course we've seen this before.. (one day gains). Didn't get a chance to listen to Levin, but one news clip said they've identified some directions in R&D and want to keep the expenditures under control. Lean and mean I suppose.
Levin may in fact bring back some investors that may have left in a haste as a result of near and longer term past mgt. practices. I'm optimistic about him. Hope it pays off eventually.